SAVA
- Cassava Sciences, Inc.
()
Overview
Company Summary
Cassava Sciences, Inc. is a biotechnology company that focuses on the development of innovative drugs for the treatment of neurodegenerative disorders, specifically Alzheimer's disease. The company is primarily engaged in the research and development of small molecule drugs that target the underlying causes of Alzheimer's and related neurodegenerative diseases.
Cassava Sciences utilizes a unique approach in the discovery and development of its pharmaceutical products. The company identifies and repurposes existing drugs already approved for other diseases into potential Alzheimer's treatments. By leveraging these compounds, Cassava Sciences aims to accelerate the path to clinical trials and potentially reduce the time, risk, and cost associated with drug development.
Their leading drug candidate is called simufilam, which is being developed as a potential disease-modifying treatment for Alzheimer's disease. Simufilam acts by modulating the protein misfolding and inflammation pathways in the brain, which are believed to contribute to the progression of Alzheimer's disease. Cassava Sciences is actively conducting clinical trials to evaluate the safety and efficacy of simufilam in patients with Alzheimer's.
In addition to their drug development activities, Cassava Sciences is also involved in significant scientific collaborations with leading research institutes, academic centers, and pharmaceutical companies. These collaborations help support their research efforts and provide access to expertise, knowledge, and additional resources.
Overall, Cassava Sciences is dedicated to making meaningful advancements in the treatment of Alzheimer's disease and improving the lives of patients and their families affected by this devastating condition.